Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
28.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
04.08. | Psyence Biomedical Ltd.: Corporate Update, August 2025 | 263 | GlobeNewswire (Europe) | NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe... ► Artikel lesen | |
01.08. | Pre-market Movers: Namib Minerals, 4D Molecular Therapeutics, CCC Intelligent Solutions, Enovix, Psyence Biomedical | 714 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).In the Green Namib Minerals (NAMM) is up over 108% at $8.26.
4D... ► Artikel lesen | |
31.07. | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | 634 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
31.07. | Psyence Biomedical stock soars after partner achieves ibogaine breakthrough | 15 | Investing.com | ||
31.07. | Psyence Biomedical Ltd.: Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production | 191 | GlobeNewswire (Europe) | NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs - a leader in the production... ► Artikel lesen | |
23.07. | PSYENCE BIOMEDICAL LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
25.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
25.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
18.06. | Psyence Biomedical Ltd.: Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 | 366 | Newsfile | Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's... ► Artikel lesen | |
17.06. | Psyence BioMed regains Nasdaq compliance following reverse stock split | 1 | Seeking Alpha | ||
17.06. | Psyence Biomedical regains Nasdaq compliance after reverse split | 4 | Investing.com | ||
17.06. | Psyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements | 277 | Newsfile | New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq... ► Artikel lesen | |
11.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
27.05. | Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi | 2 | Investing.com | ||
27.05. | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | 384 | Newsfile | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
20.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
01.05. | Psyence Biomedical to execute 1-for-7.97 reverse stock split | 5 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIOLINERX | 2,970 | 0,00 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
TRANSCODE THERAPEUTICS | 9,990 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
SILEXION THERAPEUTICS | 3,765 | -1,95 % | Silexion Therapeutics Corp: Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements | GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
MINK THERAPEUTICS | 12,400 | +4,20 % | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | ||
QIAGEN | 37,645 | -2,03 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
DYNE THERAPEUTICS | 12,580 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
MBX BIOSCIENCES | 17,330 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen | |
89BIO | 14,700 | 0,00 % | Roche To Buy 89bio For Up To $3.5 Billion | ||
BEAM THERAPEUTICS | 23,090 | -2,12 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
APOGEE THERAPEUTICS | 37,520 | -2,34 % | Apogee Therapeutics stock initiated at Outperform by RBC Capital | ||
MINERALYS THERAPEUTICS | 38,510 | -1,10 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
HARMONY BIOSCIENCES | 27,040 | 0,00 % | Deep Dive Into Harmony Biosciences Holdings Stock: Analyst Perspectives (6 Ratings) | ||
MOONLAKE IMMUNOTHERAPEUTICS | 56,38 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
EVOTEC | 6,038 | -3,05 % | Puma Aktie: Neue Gerüchte - Aumovio, Circus, Evotec, Krones und Novo Nordisk im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SCISPARC | 6,130 | 0,00 % | SciSparc Ltd. - 6-K, Report of foreign issuer |